BioCryst Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGBioCryst Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 61), indicating performance broadly in line with the market. Earnings contraction of 6% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.09 | -5.12% | BELOW |
| 50 SMA | $9.13 | -5.56% | BELOW |
| 100 SMA | $8.13 | +6.07% | ABOVE |
| 150 SMA | $7.80 | +10.51% | ABOVE |
| 200 SMA | $7.89 | +9.31% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BCRX in an uptrend right now?
BCRX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BCRX overbought or oversold?
BCRX's RSI (14) is 46. The stock is in neutral territory, neither overbought nor oversold.
Is BCRX outperforming the market?
BCRX has a Relative Strength (RS) Rating of 61 out of 99. BCRX is performing about average compared to the market.
Where is BCRX in its 52-week range?
BCRX is trading at $8.62, which is 76% of its 52-week high ($11.31) and 49% above its 52-week low ($6.00).
How volatile is BCRX?
BCRX has a Beta of 0.83 and 52-week volatility of 43%. It's less volatile than the S&P 500 - generally more stable.